Skip to main content
SpringerLink
Log in

Effects of Anti-Inflammatory Drugs on Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

This retrospective study aimed to investigate the effects of anti-inflammatory drugs (ADs) on intravenous immunoglobulin (IVIG) therapy in the acute phase of Kawasaki disease. In total, 182 pediatric patients who received IVIG therapy for Kawasaki disease between 1999 and 2013 at the Department of Pediatrics, Aomori Prefectural Central Hospital were enrolled. Patients were divided into 2 groups: an S group, including 111 patients who received single IVIG therapy with delayed administration of ADs, and a T group, including 71 patients who received concomitant AIDs with IVIG. During the study, the only ADs administered were aspirin (A: 30 mg/kg/day) or flurbiprofen (F: 3–5 mg/kg/day). Steroids were not administered to any patient. The regimen of the S group was partially used after 2004 and was used to all patients after 2009. The following clinical findings were significantly different between the S and T groups: disease onset before 2003 (0 vs. 59 %, P < 0.001) and after 2009 (70 vs. 0 %, P < 0.001), use of 2-g/kg/day IVIG therapy (100 vs. 93 %, P = 0.034), ADs type (A/F: 62/49 vs. 17/54, P < 0.001), and the prevalence of coronary artery lesions (CAL) up to (1/111 vs. 11/71, P < 0.001) and after 30 days of illness (0/111 vs. 4/71, P = 0.022). Logistic regression analysis revealed that IVIG therapy only (S group; P = 0.009) and 2-g/kg/day IVIG therapy (P = 0.015) were significant factors for CAL suppression. The findings revealed a possible negative impact of ADs on initial IVIG therapy in the acute phase of Kawasaki disease. Initial single IVIG therapy with delayed administration of ADs may be useful to suppress CAL caused by Kawasaki disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benammar C, Hichami A, Yessouufou A et al (2010) Zizyphus lotus L. (Desf.) modulates antioxidant activity and human T-cell proliferation. BMC Complement Altern Med 10:54

    Article  PubMed Central  PubMed  Google Scholar 

  2. Buckland M, Lombardi G (2009) Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol 188:197–213

    Article  CAS  PubMed  Google Scholar 

  3. Egami K, Muta H, Ishii M et al (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149:237–240

    Article  CAS  PubMed  Google Scholar 

  4. Hsieh KS, Weng KP, Lin CC et al (2004) Treatment of acute Kawasaki disease: aspirin’s role in the febril stage revisited. Pediatrics 114:e689–e693

    Article  PubMed  Google Scholar 

  5. Huang L, Mackenzie G, Ouyang N et al (2011) The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 162:1521–1533

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Inoue Y, Kaifu T, Sugahata-Tobinai A et al (2007) Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J Immunol 179:764–774

    Article  CAS  PubMed  Google Scholar 

  7. Ito H, Kiyosawa N (2002) Effectiveness of aspirin therapy in acute phase of Kawasaki disease. Prog Med 22:1640–1643

    Google Scholar 

  8. Lau AC, Duong TT, Ito S et al (2009) Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 60:2131–2141

    Article  CAS  PubMed  Google Scholar 

  9. Lee G, Lee SE, Hong YM et al (2013) Is high-dose aspirin necessary in the acute phase of Kawasaki disease? Korean Circ J 43:182–186

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Nakada T (2012) Difference in the prevalence of coronary arterial lesions in Kawasaki disease according to the time of initiation of additional aspirin or flurbiprofen therapy. Med J Aomori 57:15–19

    Google Scholar 

  11. Research committee on Kawasaki disease (1994) Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo

    Google Scholar 

  12. The Japan Kawasaki disease research committee (2002) Diagnostic guidelines of Kawasaki disease. 5th revised edn, Tokyo

  13. Yahata T, Suzuki C, Yoshikawa A et al (2014) Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J 78:188–193

    Article  CAS  PubMed  Google Scholar 

  14. Yamamoto M, Kobayashi K, Ishikawa Y et al (2010) The inhibitory effects of intravenous administration of rabbit immunoglobulin G on airway inflammation are dependent upon Fcγ receptor II b on CD11c(+) dendritic cells in a murine model. Clin Exp Immunol 162:315–324

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Zhang YY, Huang XM, Kang ML et al (2006) Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease. Zhonghua Er Ke Za Zhi 44:329–332

    PubMed  Google Scholar 

  16. Zorzi AD, Colan SD, Gauvreau K et al (1998) Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 133:254–258

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

I would like to thank all those who were involved in the medical management of the patients included in this study and Enago (www.enago.jp) for the English language review.

Conflict of interest

There are no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Aomori Prefectural Central Hospital, Higashi–Tukurimiti 2-1-1, Aomori City, Aomori Prefecture, 030-8553, Japan

    Toshimasa Nakada

Authors
  1. Toshimasa Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshimasa Nakada.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakada, T. Effects of Anti-Inflammatory Drugs on Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease. Pediatr Cardiol 36, 335–339 (2015). https://doi.org/10.1007/s00246-014-1010-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-014-1010-7

Keywords

Search

Navigation